info@thedoctorsplatform.com
Login Register
Medical Articles

Nerandomilast

PDE4B selective inhibitor (Phosphodiesterase 4B)

Description

First-in-class oral therapy approved for idiopathic pulmonary fibrosis (IPF). Slows FVC decline as monotherapy or add-on to antifibrotics.

Mechanism of action

Selective PDE4B inhibition elevates cAMP in lung fibroblasts/macrophages, reducing pro-fibrotic cytokines (TGF-β, IL-13) and extracellular matrix deposition. Anti-fibrotic and immunomodulatory.

This page is restricted. Please Login / Register to view this page.

Mechanism of action

Selective PDE4B inhibition elevates cAMP in lung fibroblasts/macrophages, reducing pro-fibrotic cytokines (TGF-β, IL-13) and extracellular matrix deposition. Anti-fibrotic and immunomodulatory.

This page is restricted. Please Login / Register to view this page.

© 2025[current_year] The Doctors Platform. All Right Reserved.

© 2025 The Doctors Platform. All Right Reserved.

Disclaimer